Navigation Links
Federal GranuFlo Lawsuits Progress, as Bernstein Liebhard LLP Notes Issuance of New Case Management Order in GranuFo Recall Litigation
Date:11/30/2013

New York, New York (PRWEB) November 30, 2013

Hundreds of GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) filed after the 2012 recall of GranuFlo and NaturaLyte dialysis drugs continue to move forward in a multidistrict litigation established in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. On November 15th, the Court issued a new Case Management Order that established a mechanism by which the defendants will disclose certain medical records pertaining to plaintiffs’ dialysis treatments at clinics owned by Fresenius Medical Care. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“This Order will ensure that plaintiffs in GranuFlo lawsuits will have access to medical records that are important to their claims,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the administration of GranuFlo and NaturaLyte during dialysis treatments.

GranuFlo Lawsuits
According to court documents, Fresenius Medical Care faces nearly 400 lawsuits pending in the federal proceeding, all of which accuse the company of failing to provide adequate warnings regarding the use of GranuFlo and NaturaLyte. The lawsuits further allege that the company continued to aggressively market both products prior to the GranuFlo recall, even after their risks became apparent in order to protect their market share.

GranuFlo and NaturaLyte were both the subject of a March 2012 Urgent Product Notification issued by Fresenius Medical Care which warned of sudden, life-threatening heart problems that could occur due to inappropriate dosing of the drugs. The New York Times reported in June 2012 that, unbeknownst to many doctors who prescribed the products, GranuFlo and NaturaLyte contained more of an ingredient the body converts to bicarbonate than rival dialysis drugs. As such, certain dosages could result in metabolic alkalosis, a dangerous condition that is caused by excessive bicarbonate in the blood. This condition raises the risk that a dialysis patient will suffer a catastrophic heart event during or shortly after treatment.*

The U.S. Food & Drug Administration (FDA) ultimately granted Class I recall status to Fresenius Medical Care’s Urgent Product Notification, which indicates that a medical product poses a significant risk of serious injury or death. According to The Times, the agency also began investigating Fresenius Medical Care shortly after learning of a memo the company had issued in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte. The agency is trying to determine if Fresenius violated federal regulations, as it chose not to inform any of the independent dialysis clinics it supplied with the products of these risks at that time.

Individuals who underwent a dialysis treatment with GranuFlo or NaturaLyte may be entitled to compensation if they experienced a catastrophic heart event within 72 hours of the treatment. To learn more about the GranuFlo recall, please visit Bernstein Liebhard LLP’s website, or visit the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.

*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.thegranuflolawsuit.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11377609.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Federal Award to Risperdal Whistleblower
2. DePuy Settlement Update: DePuy Pinnacle Lawsuits Progress in Federal Court, Rottenstein Law Group LLP Reports
3. Federal Cannabis Caucus? ~ Business of Cannabinoid Science to be Housed in Congress Notes Publius
4. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on November Status Conference in Federal Pradaxa Bleeding Litigation
5. Wright Hip Lawsuits News: Nearly 80 Lawsuits Consolidated in Federal Court, Rottenstein Law Group LLP Reports
6. DePuy ASR Lawsuit Settlement Proposal Moves Forward, as Bernstein Liebhard LLP Notes Issuance of New Order in Federal DePuy ASR Recall Litigation
7. GranuFlo Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Dialysis Lawsuits Against Fresenius Medical Care
8. DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of Remand Hearings for Federal Pinnacle Hip Lawsuits
9. Georgetown University 50-State Report Finds More Children Have Health Coverage - Attributes Gains to Successful Federal State Partnership Programs Medicaid and CHIP
10. Stryker Hip Lawsuit News: Leadership Chosen in Federal Case Consolidation in Minnesota, Rottenstein Law Group LLP Reports
11. GranuFlo Lawsuits Mount, as Filings in Federal GranuFlo Recall Litigation Approach 400, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” hits ... proof that attitude and determination can combine into the most remarkable achievements. Over ... holidays. This campaign will offer patients a new-found hope, by seizing the opportunity ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic imaging ... Heart at their tradeshow booth # 941 for the American Association of Equine ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016 Lianluo Smart Limited ... "the Company") which develops, markets and sells medical ... China and international markets, recently ... and Treatment New Progress Forum, co-hosted by the ... Province , Guangdong Provincial People,s Hospital and ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
Breaking Medicine Technology: